AlgiPharma attending Drug Delivery Conference 2026, Berlin, Germany

/in

AlgiPharma is attending the 17th Global Drug Delivery & Formulation (DDF) Summit 2026 in Berlin from May 18–20, 2026. This event is a valuable opportunity for AlgiPharma to meet industry experts to discuss advancements in drug delivery, and formulation. We are looking forward to using the opportunity to further our drug delivery program through discussions with new companies and catching up with existing partners. Attendees from AlgiPharma will be our CEO, Yngvar Berg, CMO, Dr. Yngve Mikkelsen.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma article with alginate oligosaccharides passes 1,000 hits

/in

Low Molecular Weight Alginate Oligosaccharides as Alternatives to PEG for Enhancement of the Diffusion of Cationic Nanoparticles Through Cystic Fibrosis Mucus

We’re encouraged to see strong engagement with our recent scientific publication which has now surpassed 1,000 views. The work was carried out in collaboration with Steve Hart’s first-class team at the Department of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London.
This level of interest highlights the relevance of our work and the importance of continued research in this area of LNP delivery. It’s encouraging to see the scientific and clinical community engaging with these findings.
You can access the article on PubMed here: https://pubmed.ncbi.nlm.nih.gov/39533498/
Thank you to everyone who has taken the time to read, share, and engage with our research. We welcome further feedback and discussion.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma new article published in Carbohydrate Polymers

/in

Alginate-Amphotericin B bifunctional conjugates have improved solubility and reduced toxicity

We’re very pleased to announce a new publication of AlgiPharma’s technology that highlights the potential to improve drug delivery through conjugation chemistry with AlgiPharma’s low molecular weight alginate oligosaccharides, creating novel bifunctional antimicrobial compounds. The work was carried out in collaboration with first-class research teams at NTNU and SINTEF, Trondheim, Norway.
You can access the article on PubMed here: https://pubmed.ncbi.nlm.nih.gov/41832013/

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma at Partnership Opportunities in Drug Delivery (PODD) Conference 2025, Boston, USA

/in

AlgiPharma attended and presented at this year’s Partnership Opportunities in Drug Delivery (PODD) conference in Boston. Dr. Yngve Mikkelsen (CMO) had the opportunity to present AlgiPharma’s work on alginate oligosaccharides as a next-generation delivery platform for GLP-1 receptor agonists and beyond. Our data demonstrate how AlgiPharma’s technology enhances oral bioavailability and improves mucus translocation for biologics and lipid nanoparticles, opening new frontiers in drug delivery and therapeutic design.

A huge thank you to the organizers for another excellent and engaging event. It was great to reconnect with familiar faces and meet new collaborators across the biotech and pharma landscape and the energy around innovation in drug delivery is inspiring. Attendees from AlgiPharma: CEO, Yngvar Berg, CMO, Yngve Mikkelsen, and CSO, Dr. Philip Rye.

If you couldn’t attend but would like to learn more about our work, don’t hesitate to reach out or visit www.algipharma.com

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma attending the Swedish Pharmaceutical Society meeting at AstraZeneca Mölndal, Sweden

/in

AlgiPharma is attending the 8th International Symposium on Solid Oral Dosage Forms organised by the Swedish Pharmaceutical Society and will take place on 22nd – 25th Sept at the AstraZeneca site in Mölndal, Sweden. Attendees from AlgiPharma will be by our CSO, Dr. Philip Rye, and Dr Ivana Smiljanic our Quality Manager. We are looking forward to expanding our knowledge on aspects of design, production and quality assurance of solid oral dosage forms and how these can impact the development of AlgiPharma’s technology for drug delivery.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma attending European Cystic Fibrosis Conference 2025, Milan, Italy

/in

AlgiPharma is attending the European Cystic Fibrosis Conference taking place on 4th – 6th June in Milan Italy. Looking forward to catching up with CF colleagues and using the opportunity for further discussions with potential commercial partners. Attendees from AlgiPharma will be our CEO, Yngvar Berg, CSO, Dr. Philip Rye, and Dr Charles Johnson from our board of directors.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma presenting at Formulation and Delivery 2024, London, UK

/in

AlgiPharma presenting at Formulation and Delivery 2024, London, UK

We are delighted to have been invited to speak at the Formulation & Delivery 2024 conference, taking place 25th – 26th April in London, UK.

AlgiPharma will have two separate presentations highlighting it’s alginate technology for use in the drug delivery of lipid nanoparticles by inhalation and for oral uptake of peptides. Presentations will be by our Chief Scientific Officer, Dr. Philip Rye, and Chief Medical Officer, Dr. Yngve Mikkelsen.

Join us in London next week or follow up with us directly to get a copy of the presentations and explore commercial opportunities.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma is recruiting again!

/in ,

R&D Project Manager at AlgiPharma

Application Deadline:  28.01.2024

The candidate will proactively manage the day-to-day running of multiple R&D projects, coordinating with key internal and external stakeholders to advance our portfolio of alginate oligosaccharide technologies for drug delivery, drug conjugates and stand-alone API for cystic fibrosis, COPD and infectious diseases. In addition to the basic project management activities, the candidate will also focus on the R&D development, formulation, and manufacturing elements of these projects in cooperation with internal and external parties, both nationally and internationally. The candidate will work collaboratively with multi-faceted teams including external academic and commercial CROs and suppliers. The candidate will have demonstrated clear organizational skills and experience of project management in the biotech/biopharma industry and have relevant experience in R&D and chemical/biotechnological manufacturing. Previous experience establishing effective working relationships in a virtual organization is an asset. The candidate will report directly to the Chief Scientific Officer.

The ideal candidate has:

  • PhD in chemical/biotechnological science or related field.
  • 5+ years’ experience of project management in the biotechnology or pharmaceutical industry.
  • Experience and a successful track record in managing multiple project accounts and familiarity applying to national and international funding agencies and reporting on project grants.
  • Proficiency in Microsoft Office programs and tools.
  • Excellent communication and presentation skills in Norwegian and English.
  • Having studied or worked outside Norway for at least a year is an advantage.

 

About AlgiPharma

AlgiPharma is a clinical stage biopharmaceutical company with a focus on developing its proprietary alginate technology for:

  • Drug delivery – technology platform for small and large molecule-based drugs.
  • Drug conjugates – adding functionality and reducing toxicity of the parent compound.
  • Stand-alone API – for respiratory diseases such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical-scale production capabilities and a broad family of patents protects its technology.

AlgiPharma aims to address unmet medical needs and fight diseases effectively through innovative alginate technologies. Our alginate technology targets diseases with a clinical need to mitigate abnormal mucus accumulation, non-invasive drug delivery challenges, microbial infection, biofilm formation and antibiotic resistance.

AlgiPharma has orphan drug status with EMA and FDA and has secured up to USD 47 million in non-dilutive funding from government and NGO support including NOK 150 million from the American Cystic Fibrosis Foundation in developing its first drug candidate for people with CF.

AlgiPharma has completed six clinical trials, showing exemplary safety and tolerability.

AlgiPharma technology has a wide range of disease applications with particular emphasis on inhalation and oral drug delivery.

Building on the success and recent developments of the technology, the team at AlgiPharma is expanding to meet the demands of significant external interest in our technology.

 

What AlgiPharma offers

  • An engaging and dynamic working environment at a company that has multiple commercial development opportunities.
  • Opportunity for self-development, such as training courses and conference.
  • Flexible working hours to maintain a good work-life balance.
  • Senior management health insurance plan for all.
  • Excellent remuneration.

 

We are interested in hearing from high caliber, energetic candidates to join the AlgiPharma team at our Norwegian office in Sandvika. Preference will be given to those candidates already resident in Norway or who are already eligible to work in Norway.

 

Please address questions regarding the position to:

Mr. Arne Dessen, COO / Chairman  BoD, arne.dessen@algipharma.com,

AlgiPharma Presenting at the Lipid Nanoparticle Development Europe Summit

/in

We are delighted to have been invited to speak at the 2nd Lipid Nanoparticle Development Europe Summit, taking place 17-19th October 2023, in Amsterdam.

With lipid nanoparticles (LNPs) moving beyond mRNA vaccines, AlgiPharma is developing its technology to improve the delivery and efficacy of LNP therapeutics. Dr. Philip Rye, Chief Scientific Officer at AlgiPharma will present on aspects of Lipid Nanoparticle Drug Delivery for Chronic Lung Diseases, and highlight some of the latest findings with AlgiPharma’s technology.

Join us in Amsterdam in October (see program here: https://ter.li/6fxvbr) or follow up with us directly to explore commercial opportunities.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

Delivery platforms for nanoparticles, small and large molecule based drugs.

Drug conjugates, adding functionality and reducing toxicity of parent compound.

API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma announces the appointment of Dr. Preston W. Campbell MD to the Board

/in

We are extremely pleased to announce the appointment of Preston W. Campbell to the AlgiPharma Board as a non-executive Board Member. His experience and wisdom will be invaluable in guiding the AlgiPharma team and their alginate technology closer to market.

 

Dr. Preston Campbell served at the Cystic Fibrosis Foundation for 25 years where he focused on Cystic Fibrosis (CF) drug discovery and development. After a successful career as a Pediatric Pulmonologist at Vanderbilt University, he joined the Foundation as Executive Vice President of Medical Affairs in 1998. In 2015, he became the Foundation’s President and CEO. During his tenure at the Foundation, he oversaw the Foundation’s research initiatives and its collaborative drug discovery and development program. He has extensive experience with numerous companies helping them navigate discovery or clinical development efforts. These resulted in the approval of twelve CF therapies including four that treat the basic defect in CF. The most recent was Trikafta, which benefits 93 percent of people with the disease. The survival of people with CF during this time has increased dramatically. He retired in 2023 and remains involved with drug discovery and development as an independent consultant. He is a citizen of the United States of America.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com